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Increased interictal cerebral glucose metabolism
in a cortical-subcortical network in drug naive
patients with crytogenic temporal lobe epilepsy
Massimo Franceschi, Giovanni Lucignani, Angelo Del Sole, Chiara Grana, Sergio Bressi,
Fabio Minicucci, Cristina Messa, Maria Paola Canevini, Ferruccio Fazio
Abstract
Positron emission tomography with ['8F]-
2-fluoro-2-deoxy-D-glucose ([18F]FDG)
has been used to assess the pattern of
cerebral metabolism in different types of
epilepsies. However, PET with [18F]FDG
has never been used to evaluate drug
naive patients with cryptogenic temporal
lobe epilepsy, in whom the mechanism of
origin and diffusion of the epileptic dis-
charge may differ from that underlying
other epilepsies. In a group of patients
with cryptogenic temporal lobe epilepsy,
never treated with antiepileptic drugs,
evidence has been found of significant
interictal glucose hypermetabolism in a
bilateral neural network including the
temporal lobes, thalami, basal ganglia,
and cingular cortices. The metabolism in
these areas and frontal lateral cortex
enables the correct classification of all
patients with temporal lobe epilepsy and
controls by discriminant function analy-
sis. Other cortical areas-namely, frontal
basal and lateral, temporal mesial, and
cerebellar cortices-had bilateral
increases of glucose metabolism ranging
from 10 to 15% of normal controls,
although lacking stringent statistical sig-
nificance. This metabolic pattern could
represent a pathophysiological state of
hyperactivity predisposing to epileptic
discharge generation or diffusion, or else
a network of inhibitory circuits activated
to prevent the diffusion of the epileptic
discharge.
(7 Neurol Neurosurg Psychiatry 1995;59:427-431)
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Cryptogenic partial epilepsies are disorders
with an unknown and occult aetiology.'
Although MRI has greatly improved our abil-
ity to uncover anatomical lesions in these
patients,2 our ignorance of a presumed cause
may be due to low sensitivity of our diagnos-
tic tools.
The assessment of cerebral metabolism by
PET with ['8F]-2-fluoro-2-deoxy-D-glucose
(['8F]FDG) has improved our knowledge on
the metabolism in the epileptogenic zone and
on the pattern of diffusion of the epileptic dis-
charge in different types of epilepsies.'-6
Indeed, PET/['8F]FDG now has a well estab-
lished clinical role in the presurgical evalua-
tion of patients with drug resistant temporal
lobe epilepsy.7-9 Temporal lobe epilepsy is
often symptomatic of cerebral lesions which
are commonly found by MRI,'0 but are some-
times detectable only by PET/['8F]FDG.'0
Different mechanisms of origin and diffu-
sion of the epileptic discharge may underlie
symptomatic and cryptogenic temporal lobe
epilepsies. The assessment of cerebral metab-
olism in patients with cryptogenic temporal
lobe epilepsy could help to understand the
physiopathological mechanisms of this type of
seizure and eventually to reclassify individual
patients.
The purpose of this study was the assess-
ment of interictal regional cerebral glucose
utilisation (rCMRglu) in patients not taking
drugs and in whom the clinical diagnosis of
cryptogenic epilepsy was made for the first
time just before the study. Thus we investi-
gated the early phases of cryptogenic tempo-
ral lobe epilepsy and avoided the possibility of
artifactual findings due to the effects of
antiepileptic treatment.
Subjects and methods
PATIENTS
We studied 13 consecutive patients (10
women and three men, mean age 31-8, range
17-53 years) in whom the diagnosis of cryp-
togenic temporal lobe epilepsy was made
according to standard criteria (table 1).1
None of the patients with temporal lobe
epilepsy had ever had a diagnosis of epilepsy
before the enrolment in the study, not even
those with a long history of disease, probably
because of the little impact on their daily life
of rare and benign partial seizures. For this
reason they had never been treated with
antiepileptic drugs.
Their first seizure occurred between six
months and 27 years before the diagnosis
(mean 4 (SD 7) years) and they reported a
variable number of seizures (mean 8 (SD 12);
range 3-50) during the entire course of the
disease.
Eleven patients had only complex partial
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Table 1 Clinicalfeatures ofpatients with temporal lobe epilepsy
Patient Duration Type of
No Sex Age of disease (y) seizures EEG focus
1 F 26 0-5 CP T left
2 F 28 1 CP + gen Bitemporal
3 M 48 1 CP Tleft
4 F 27 4 CP + gen T left
5 F 17 1 CP Tright
6 F 24 3 CP + SP T left
7 M 53 27 CP + gen T right
8 F 24 5 CP Tleft
9 F 20 0 5 CP + gen Bitemporal
10 F 23 0 5 CP T left
11 M 47 4 SP + gen T right
12 F 41 3 CP + SP Tright
13 F 40 10 SP + gen T right
CP = Complex partial seizures; SP = simple partial seizures; gen = secondarily generalised
seizures; T = temporal lobe.
seizures and two patients had both simple
and complex partial seizures. Six patients
reported one to three episodes of secondary
generalisation, usually during sleep. Interictal
waking or sleep EEG recordings showed
epileptic abnormalities localised in the left
(six patients), in the right (five patients), or in
both (two patients) temporal regions. An ictal
EEG could not be recorded in any of the
patients examined.
None of the patients had relevant
neurological or systemic disease, and brain
MRI was normal; MRI was performed with a
1*5 Tesla superconducting unit, using
contiguous axial and coronal slides of
5 mm thickness and multiple spin echo
sequences (TR = 2400 ms; Ti = 500/17 ms;
T2 = 15/90 ms). Because the accuracy of
MRI evaluation is critical in the diagnosis of
cryptogenic temporal lobe epilepsy, an expert
unblind neuroradiologist was asked to rule
out possible structural abnormalities in the
mesial temporal lobe.
Patients underwent the PET/['8F]FDG
study at least three days after their last
seizure. Scalp EEG monitoring, initiated at
least 30 minutes before giving ['8F]FDG, and
carried out up to the end of the PET exami-
nation, did not show subclinical seizures or
epileptic patterns other than those in the
patients' previous EEG recordings.
CONTROLS
Control subjects were 13 normal healthy age
matched volunteers, mean age 34-2, range
18-59 years, and with no history of drugs or
seizures.
Permission for the study was given by the
ethics committee of the Scientific Institute H
San Raffaele.
PET METHODS
The ['8F]FDG was synthesised as previously
described" with a compact automated mod-
ule connected to the cyclotron (Siemens-CTI
RDS 112 cyclotron, Siemens/CPS, Knoxville,
TN, USA) and used within one hour of its
preparation. Quality control procedures for
the tracers were carried out routinely
according to methods previously described
and [18F]FDG with radiochemical purity
higher than 95% was used.'2 We used an
ECAT 931/04-12 tomograph (CPS/Siemens,
Knoxville, TN, USA) with a transverse field
of view of 55-5 cm and an axial field of view
of 5-4 cm. All subjects were studied in the
resting state with their eyes open and ears
unplugged. Before each study a 20 gauge
teflon catheter was inserted into the radial
artery, under local anaesthesia; the patients
were then positioned in the PET scanner and
their heads were restrained by a customised
head holder. The orbitomeatal line was sym-
metrically defined with the aid of low energy
laser beams and skin marks and the PET
gantry was aligned to obtain axial slices paral-
lel to the orbitomeatal line. Two 10 minute
consecutive transmission scans, one for each
bed position necessary to examine the whole
brain, were performed with a 68Ge/68Ga
source external to the subject to measure the
coefficients to correct for attenuation of the
emitted photons. At the end of the transmis-
sion scan each subject received an intra-
venous injection of about 250 MBq of
['8F]FDG. Timed arterial blood samples were
collected continuously for the first minute
after the tracer injection and then at increas-
ing intervals throughout the PET study, to
assay the plasma concentration of glucose
and '8F. Emission scans were carried out
between 45 and 70 minutes after intravenous
[18F]FDG injection. Data were acquired from
two sets of seven equally spaced transaxial
planes (four direct and three cross planes;
slice thickness 6-75 mm) parallel to the
orbitomeatal line and covering an axial field
of view of 10-8 cm. Scans were reconstructed
with a Hann Filter with a cut off frequency of
0 5 cycles per pixel. Under these conditions,
the spatial resolution in the image plane was
8 mm full width at half maximum. Each
image was reconstructed on a 128 x 128
matrix with a pixel size of 1-56 mm.
Correction for attenuation of the 512 KeV y
rays by the tissue was performed with the
coefficients obtained from the transmission
scan. Average values of regional cerebral
metabolic rate for glucose (rCMRglu) were
calculated in each region of interest based on
the plasma glucose and 18F assays according
to a model with the three rate constants oper-
ational equation of Sokoloff et al'2 using the
kinetic constants and lumped constant
reported by Reivich et al.'3
PET DATA ANALYSIS
Reconstructed images were transferred to a
SUN SPARC workstation for the analysis.
Circular regions of interest, with a diameter
of 9-6 mm (1 5 full width at half maximum),
were drawn on 14 anatomofunctional corti-
cal, subcortical, and cerebellar structures,
identified from the atlas of Damasio and
Damasio.'4 Mean rCMRglu values for each of
the 14 structures were calculated by averag-
ing the rCMRglu values of the multiple
regions of interest included in each anatomi-
cal region. These average values were used
for the data analysis.
STATISTICAL ANALYSIS
All analyses were with the SPSS package.'5
A repeated measures analysis of variance
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(ANOVA) with one between subject factor
(temporal lobe epilepsy patients v normal
controls) and two within subject factors
(cerebral regions (the 14 regions listed in
table 2) and hemisphere (left and right)) was
performed. The mean and interaction effects,
when significant, were tested with the appro-
priate univariate ANOVA and further
analysed with Bonferroni's correction for
multiple comparisons set at P < 0-05.
To remove the potential confounding
effect of within and between subject variation
of global hemispheric activity on rCMRglu in
the post hoc analyses, we used univariate
analyses of covariance (ANCOVA). The ade-
quacy of the covariate model for each region
was tested evaluating the homogeneity of
slopes assumption (parallelism of covariate
between groups).'6
A stepwise feed forward discriminant func-
tion analysis was used to provide additional
information about which metabolic variables
were most efficient at differentiating patients
with temporal lobe epilepsy from normal con-
trols. The discriminant function analysis is a
multivariate linear method which examines a
series of dependent variables (rCMRUglu) of
two or more groups, calculates the "discrimi-
nant score", and, on the basis of that, enables
the classification of individual subjects within
each group. Only those variables which met
the criterion of an 0-05 level of significance
were entered into the equation. The classifi-
cation accuracy was determined when all the
variables had been selected.
Non-parametric Kendall's tau rank corre-
lations with corrections for tied values were
used to assess the relation between clinical
scores and regional metabolic rates.
Results
rCMRglU IN THE TEMPORAL LOBE EPILEPSY
GROUP V CONTROL GROUP
Table 2 summarises the mean rCMRglu val-
ues measured in the two hemispheres and in
14 discrete cerebral regions, in patients with
temporal lobe epilepsy and controls.
A significant group effect
(F(1,48) = 15-61, P < 0-001) and a regional
effect (F(13,312) = 187-30, P < 0-0001),
but no significant hemispheric effect (F(1,48)
= 0-05, NS) were shown by a repeated mea-
sures ANOVA. The group x regions interac-
tion was significant (F(13,312) = 7-04,
P = 0-0001), thus indicating a different
rCMRglu between patients and controls. No
other significant interactions were found.
The post hoc analysis of regional differ-
ences showed a significant bilateral increase
of metabolic activity in the lateral
(P < 0-0002) and polar (P < 0-0004) tem-
poral regions, in the thalamus (P < 0-002),
caudate (P < 0-002), pallidum/putamen
complex (P < 0-002), and anterior cingulate
cortex (P < 0-002).
The significant differences in the post hoc
analyses were confirmed even when the effect
of global hemispheric activity on rCMRglu
was removed by covariance (table 2).
The stepwise discriminant function analy-
sis identified six regions the metabolism of
which showed the greatest statistical power in
discriminating between patients with tempo-
ral lobe epilepsy and normal controls. These
areas constituted a bilateral network includ-
ing lateral and polar temporal regions, lateral
frontal regions, thalami, caudates, and ante-
rior cingulate cortices (Wilks' Lambda: 0-24,
F = 23-71; P < 0-00001).
MEASURES OF METABOLISM IN INDIVIDUAL
PATIENTS WITH TEMPORAL LOBE EPILEPSY
No significant correlations were found
between rCMRglu and sex, age, side ofEEG
abnormalities, duration of disease, and types
and number of seizures. No patients had
regional or hemispheric hypometabolism
below the 5th percentile of controls.
Discussion
In a group of patients with cryptogenic tem-
poral lobe epilepsy who were never treated
with antiepileptic drugs, we have found evi-
dence of significant interictal hypermetabo-
Table 2 rCMRgk (mg 1OOg-' min-') in patients (n = 13) and controls (n = 13)
Left hemisphere Right hemisphere
F ANCOVA F ANCOVA
TLE patients Controls value valut TLE patients Controls value valuet
Hemisphere 6-81 (0-86) (6-29-7-33) 6-07 (0-60) (5-70-6-43) 7-95 - 6-78 (0-75) (6-32-7-23) 6-08 (0-57) (5-73-6-42) 6-73 -Frontal:
Basal 6-49 (0-86) (5-97-7-02) 5-90 (0-45) (5-62-6 17) 4-80 2-84 6-41 (0-83) (5-91-6-91) 5-82 (0-46) (5-54-6-10) 4-90 2-65Lateral 7-01 (0-87) (6-48-7-54) 6-22 (0-62) (5-84-6-59) 7-29 4-16 6-92 (0-80) (6-43-7-40) 6-19 (0-68) (5-77-6-60) 6-12 4-10Rolandic 6-92 (0-71) (6-49-7-30) 6-49 (0-64) (6-10-6-88) 2-40 1-64 6-89 (0-76) (6-42-7-35) 6-48 (0-70) (6-06-6-91) 2-09 1-47Cingulate 7-01 (0-87) (6-48-7-53) 5-95 (0-76) (5-49-6-40) 12-42* 11-22* 6-82 (0-81) (6-33-7-31) 5-90 (0-59) (5-54-6-26) 11-83* 10-55*Parietal 6-96 (0-90) (6-41-7-50) 6-26 (0-58) (5-95-6-58) 5-87 4-42 6-90 (0-81) (6-41-7-39) 6-39 (0-61) (6-01-6-76) 3-18 3-94Temporal:
Polar 5-05 (0-66) (4-65-5-43) 4-27 (0-57) (3-92-4-61) 14-39* 9-38* 5-04 (0-53) (4-72-5-36) 4-26 (0-43) (4-12-4-40) 14-25* 9.97*Lateral 6-78 (0-73) (6-34-7-23) 5-77 (0-47) (5-48-6-05) 20-18* 20-35* 6-66 (0-60) (6-30-7-03) 5-76 (0-44) (5-49-6-03) 15-94* 18-13*Mesial 5-93 (0-79) (5-45-6-41) 5-29 (0-56) (4-95-5-63) 6-73 3-21 5-75 (0-58) (5-40-6-11) 5-27 (0-53) (4-95-5-60) 5-75 3-08Occipital:
Lateral 6-44 (0-62) (6-06-6-82) 6-35 (0-72) (5-91-6-78) 0-25 2-51 6-46 (0-62) (6-08-6-83) 6-45 (0-91) (5-90-7-01) 0-82 2-58Calcarine 8-03 (1-15) (7-34-8-73) 7-23 (0-90) (6-68-7-78) 2-97 1-86 7-69 (1-13) (7-00-8-38) 7-68 (0-89) (6-60-7-68) 1-80 1-98Putamen/
pallidum 7-68 (0-85) (7-16-8-19) 6-57 (0-72) (6-13-7-01) 12-15* 10-31* 7-51 (0-96) (6-92-8-09) 6-60 (0-56) (6-23-6-93) 10-18* 9-88*Caudate 7-30 (0-65) (6-90-7-69) 6-26 (0-58) (5-91-6-61) 15-09* 10-43* 7-17 (0-70) (6-74-7-59) 6-36 (0-60) (5-99-6-72) 10-93* 9-87*Thalamus 7-22 (0-81) (6-73-7-70) 6-21 (0-73) (5-77-6-66) 10-76* 9-38* 7-33 (0-83) (6-83-7-84) 6-28 (0-76) (5-82-6-74) 10-10* 9-89*Cerebellum 6-04 (0-70) (5-61-6-46) 5-40 (0-68) (4-99-5-81) 2-99 1-26 6-02 (0-65) (5-62-6-41) 5-40 (0-62) (5-03-5-78) 2-56 1-74
Values are means (SD) (95% CI); TLE = temporal lobe epilepsy.
tF values adjusted for global hemispheric metabolism (one way ANCOVA).
*Significance level set at P < 0-003 according to Bonferroni's correction.
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lism in a bilateral neural network including
the temporal lobes, thalami, basal ganglia,
and cingular cortices. Applying the metabo-
lism of these areas and of lateral frontal
regions in the model of discriminant function
analysis, all patients with temporal lobe
epilepsy and normal controls could be cor-
rectly assigned to each category. Although
lacking stringent statistical significance, sev-
eral other cortical areas had bilateral increases
of rCMRglu ranging from 10% to 15%.
These areas were the frontal basal, frontal lat-
eral, temporal mesial, and cerebellar cortices,
all of which are known to be functionally cor-
related to the significantly hypermetabolic
network. By contrast, the rolandic, parietal,
and occipital areas showed minimal increases,
ranging from 0 5% to 7% in comparison with
normal subjects.
This finding is surprising because previous
interictal studies of patients with refractory
temporal lobe epilepsy have shown in most
cases unilateral areas of temporal hypometab-
olism, usually concordant with the side of the
EEG abnormalities and with the site of a
morphological lesion.'7 Interictal hypermetab-
olism has been occasionally reported: in
episodic cases of children with refractory tem-
poral lobe epilepsy,'8 bilaterally in lenticular
nuclei of children with infantile spasms,' and
in the thalamus contralateral to mesial gliosis
in patients with refractory temporal lobe
epilepsy.'9 On the contrary, a widespread
hypermetabolism is usually found during
seizures or in the postictal period in patients
with refractory temporal lobe epilepsy.3 17 18
Hypermetabolism due to seizures can be rea-
sonably excluded in our patients as they had
been seizure free for at least three days before
the PET/['8F]FDG study. Moreover, EEG
monitoring excluded seizures 30 minutes
before and during the PET/['8F]FDG study.
The unlikely possibility of a localised subclin-
ical discharge in the mesial structures unde-
tected by scalp EEG cannot be ruled out.
The apparent discrepancies between these
and previous findings can have several expla-
nations. The population of epileptic patients
examined in this study was different from
those previously examined. In particular, our
patients: (a) had a diagnosis of cryptogenic
and not of symptomatic temporal lobe
epilepsy; (b) had a mild illness; (c) were not
taking medication. Patients with cryptogenic
epilepsies are less commonly drug resistant
and less severely ill than patients with symp-
tomatic epilepsies. Abnormal MRI findings,
including mesial gliosis or neoplasms, are
often found in patients with refractory tempo-
ral lobe epilepsy. These patients, often with
long lasting, frequent, and severe seizures,
may have had a spontaneous kindling phe-
nomenon, or even sequelae of cerebral
trauma, further complicating cerebral meta-
bolic patterns. Patients with cryptogenic tem-
poral lobe epilepsy and normal MRI may
have a pattern of origin and diffusion of
epileptogenic discharges different from that of
patients with temporal lobe epilepsy refrac-
tory to antiepileptic drugs. All patients with
refractory temporal lobe epilepsy studied with
PET/['8F]FDG and reported in the medical
literature were having long term antiepileptic
treatment, often with more than one drug.
This was likely to induce a decrease in cere-
bral glucose metabolism.20
Our finding of a bilateral hypermetabolic
network contrasts with the hypothesis of well
localised epileptogenic zones underlying the
pathophysiology of cryptogenic temporal lobe
epilepsy. This pattern is, however, in agree-
ment with the clinical finding that often in
cryptogenic temporal lobe epilepsy neither
seizure phenomenology nor EEG are clearly
lateralising or localising the epileptogenic
zone. For example, in our sample no patient
had lateralising signs in their seizures (which
were mainly amygdalohippocampal' and sec-
ondarily generalised), two patients out of 13
had bilateral EEG abnormalities, and six
patients showed lateralising EEGs only dur-
ing sleep recordings.
The bilateral hypermetabolic network
found in a group of untreated patients with
cryptogenic temporal lobe epilepsy could rep-
resent a pathophysiological state of hyperac-
tivity predisposing to epileptic discharge
generation or diffusion, or a network of
inhibitory circuits activated to prevent the dif-
fusion of the epileptic discharge originating
from a localised epileptogenic zone. In refrac-
tory symptomatic temporal lobe epilepsy,
focal neuronal loss and gliosis or alterations
of synaptic processes seem to be the common
causes of interictal glucose hypometabolism,21
whereas the ictal hypermetabolism could be
related to energy consuming epileptic
activity.3 '7 Postictal hypermetabolism seems
to be due to energy expenditure of inhibitory
circuits for the restoration of normal mem-
brane polarisation and chemical homeostasis.
A similar mechanism could explain our find-
ing of hypermetabolic bilateral networks in
patients with cryptogenic temporal lobe
epilepsy. Against this hypothesis are the low
frequency of their seizures, the mildness of
the disease, and the long time (at least 72
hours) between the last seizure and the
PET/['8F]FDG study. The hypothesis that
the hyperactive network is the underlying
pathophysiological basis of the disease seems
to be more reasonable and could be con-
firmed by an ongoing follow up study in the
same group of patients during chronic effec-
tive treatment with carbamazepine. Indeed, it
cannot be ruled out that hypermetabolic net-
works may actually underlie most epileptic
processes and could also be found in patients
with refractory temporal lobe epilepsy if it
were possible to study them when they were
not taking drugs.
Whichever is the neurophysiological inter-
pretation, the finding of a hypermetabolic
network in cryptogenic temporal lobe
epilepsy suggests the existence of different
mechanisms of origin and diffusion of the
epileptic discharge and of different functional
balance between "normal" and "lesioned"
cerebral areas in different types of epilepsies.
This in turn points out the need for metabolic
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studies in other types of epilepsies, such as
idiopathic epilepsies or situation related
epileptic syndromes.
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